Clinical Trials Logo

Clinical Trial Summary

Cognitive behavior therapy is the most effective treatment of obsessive-compulsive disorder. However, the majority of treated patients remain symptomatic. The metacognitive therapy by Wells (1997) could achieve substantial gains in first pilot studies. The purpose of this study is to investigate this approach with a randomized controlled trial by comparing metacognitive therapy with exposure and response prevention for obsessive-compulsive disorder.


Clinical Trial Description

The purpose of this study is to investigate metacognitive therapy by Wells (1997) with a randomized controlled trial by comparing metacognitive therapy with exposure and response prevention for obsessive-compulsive disorder. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02867449
Study type Interventional
Source University of Leipzig
Contact
Status Completed
Phase N/A
Start date June 2016
Completion date January 2020

See also
  Status Clinical Trial Phase
Recruiting NCT01949753 - Influence of Pregnenolone on Exposure Therapy in Obsessive-compulsive Disorder Phase 2
Completed NCT02267629 - Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder Phase 2
Recruiting NCT04042038 - Neural Predictors and Neural Changes Associated With Cognitive Behavior Therapy for Obssesive Compulsive Disorder N/A
Completed NCT01368510 - Intensive Cognitive-Behavioral Therapy For Obsessive-Compulsive Disorder N/A
Not yet recruiting NCT05422469 - OCD Biomarker Survey Employing sEEG and Stimulation: The OBSESS Trial N/A
Active, not recruiting NCT03300947 - Psilocybin for Treatment of Obsessive Compulsive Disorder Phase 1
Recruiting NCT02773082 - Reclaimâ„¢ Deep Brain Stimulation (DBS) Therapy for Obsessive-Compulsive Disorder (OCD) N/A
Not yet recruiting NCT06360991 - DBS for Treatment-resistant Obsessive-compulsive Disorder N/A
Completed NCT03605316 - Deep Electrical Neuromodulation in Obsessive-compulsive Disorder